Cargando…
Cannabis et neurodéveloppement()
Brain development is a complex phenomenon, stretching from fetal life to adolescence, during which brain maturation proceeds through a series of ordered events including critical periods of plasticity. The brain is particularly sensitive to the environment during these changes. The endocannabinoid s...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
l'Académie nationale de médecine. Published by Elsevier Masson SAS.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7162744/ https://www.ncbi.nlm.nih.gov/pubmed/32308209 http://dx.doi.org/10.1016/j.banm.2020.04.002 |
_version_ | 1783523082266214400 |
---|---|
author | Krebs, M.-O. Demars, F. Frajerman, A. Kebir, O. Jay, T. |
author_facet | Krebs, M.-O. Demars, F. Frajerman, A. Kebir, O. Jay, T. |
author_sort | Krebs, M.-O. |
collection | PubMed |
description | Brain development is a complex phenomenon, stretching from fetal life to adolescence, during which brain maturation proceeds through a series of ordered events including critical periods of plasticity. The brain is particularly sensitive to the environment during these changes. The endocannabinoid system participates directly and indirectly in these plasticity and maturation processes. The main psychoactive component of cannabis, the delta-9-tetrahydrocanabinol, can cross the placental barrier, is present in breastmilk and diffuses in the brain. It interacts with the endocannabinoid signaling, especially through the activation of cannabinoid receptors 1 CB1R, which can lead to abnormal neurodevelopmental processes and neuronal circuits functions. Therefore, exposure to cannabis in utero, in perinatal phase, as well as during the adolescence disrupts the brain maturation and can cause disturbances on the cognitive, psychotic and addictive levels that persist far beyond the period of exposure. Several factors modulate the risk of such complications, but studies performed in animal models as well as in human cohorts have shown that exposure during both the critical perinatal and adolescence phases is a risk factor per se. Current knowledge encourages the dissemination of objective information to young people, to prevent and limit early exposure and its consequences. |
format | Online Article Text |
id | pubmed-7162744 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | l'Académie nationale de médecine. Published by Elsevier Masson SAS. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71627442020-04-17 Cannabis et neurodéveloppement() Krebs, M.-O. Demars, F. Frajerman, A. Kebir, O. Jay, T. Bull Acad Natl Med Article Brain development is a complex phenomenon, stretching from fetal life to adolescence, during which brain maturation proceeds through a series of ordered events including critical periods of plasticity. The brain is particularly sensitive to the environment during these changes. The endocannabinoid system participates directly and indirectly in these plasticity and maturation processes. The main psychoactive component of cannabis, the delta-9-tetrahydrocanabinol, can cross the placental barrier, is present in breastmilk and diffuses in the brain. It interacts with the endocannabinoid signaling, especially through the activation of cannabinoid receptors 1 CB1R, which can lead to abnormal neurodevelopmental processes and neuronal circuits functions. Therefore, exposure to cannabis in utero, in perinatal phase, as well as during the adolescence disrupts the brain maturation and can cause disturbances on the cognitive, psychotic and addictive levels that persist far beyond the period of exposure. Several factors modulate the risk of such complications, but studies performed in animal models as well as in human cohorts have shown that exposure during both the critical perinatal and adolescence phases is a risk factor per se. Current knowledge encourages the dissemination of objective information to young people, to prevent and limit early exposure and its consequences. l'Académie nationale de médecine. Published by Elsevier Masson SAS. 2020-06 2020-04-17 /pmc/articles/PMC7162744/ /pubmed/32308209 http://dx.doi.org/10.1016/j.banm.2020.04.002 Text en © 2020 l'Académie nationale de médecine. Published by Elsevier Masson SAS. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Krebs, M.-O. Demars, F. Frajerman, A. Kebir, O. Jay, T. Cannabis et neurodéveloppement() |
title | Cannabis et neurodéveloppement() |
title_full | Cannabis et neurodéveloppement() |
title_fullStr | Cannabis et neurodéveloppement() |
title_full_unstemmed | Cannabis et neurodéveloppement() |
title_short | Cannabis et neurodéveloppement() |
title_sort | cannabis et neurodéveloppement() |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7162744/ https://www.ncbi.nlm.nih.gov/pubmed/32308209 http://dx.doi.org/10.1016/j.banm.2020.04.002 |
work_keys_str_mv | AT krebsmo cannabisetneurodeveloppement AT demarsf cannabisetneurodeveloppement AT frajermana cannabisetneurodeveloppement AT kebiro cannabisetneurodeveloppement AT jayt cannabisetneurodeveloppement |